ResMed Inc.

RMD Healthcare Medical Instruments & Supplies

ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025.

Revenue
+5.93%
EPS
+23.1%
Free cash flow
−9.79%
Total debt
−38.9%

Quarter to September 2026, against a year earlier

235.22 4.09 −1.71%
Market cap
$33.7B
P/E
21.7×
Fwd P/E
19.6×
Dividend yield
1.03%
F-score
6/9
Altman Z
10.00
Beneish M
−2.59
Dividend safety
96/100

ResMed Inc. 10-Q filed May 1, 2026

Fiscal Q3 2026 · Period ended Mar 31, 2026 · Filed · accepted 6:19 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jan 30, 2026: 5 added · 1 removed · 27 modified; 32 with only figures updated

  1. Modified · Management’s Discussion and Analysis of Financial Condition and Results of Operations

    Net revenue from masks and other for the three months ended DecemberMarch 31, 20252026 increased to $529.7524.8 million from $456.3454.4 million for the three months ended DecemberMarch 31, 20242025, an increase of $73.470.4 million or 1615%, including an increase of 1614% in the U.S., Canada and Latin America and an increase of 1720% in combined Europe, Asia and other markets (an 8a 10% increase on a constant currency basis). Excluding the impact of foreign currency movements, masks and other sales for the three months ended DecemberMarch 31, 20252026 increased by 1412%.